Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1104-1111

  Mita, M M ^a   Poplin, E ^b   Britten, C D ^c   Tap, W D ^c,d   Rubin, E H ^e   Scott, B B ^e   Berk, L ^f   Rivera, V M ^f   Loewy, J W ^f   Dodion, P ^f   Haluska, F ^f   Sarantopoulos, J ^a   Mita, A ^a   Tolcher, A ^a  

^a CTRC Institute for Drug Development   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

MTOR; Rapamycin; Ridaforolimus; Sarcoma

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RIDAFOROLIMUS;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CEREBELLUM INFARCTION; CHEMOTHERAPY INDUCED EMESIS; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE DEFICIENCY; INTERSTITIAL LUNG DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUTH ULCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SARCOMA; SEPSIS; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84875633556     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds602     Document Type: Article

References (24)

1. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 3151-3171.
2. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-262.
3. Hennessy BT, Smith DL, Ram PT et al.. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
4. Fingar DC, Richardson CJ, Tee AR et al.. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004; 24: 200-216.
5. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9: 667-676.
6. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-2963.
7. Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature 2001; 411: 355-365.
8. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371-377.
9. Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA 2001; 98: 7037-7044.
10. Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 2010; 15: 236-245.
11. Ciuffreda L, Di Sanza C, Incani UC et al.. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 2010; 10: 484-495.
12. Mita MM, Mita AC, Chu QS et al.. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008; 26: 361-367.
13. Squillace RM, Miller D, Cookson M et al.. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther 2011; 10(2): 1959-1968.
14. Rivera VM, Squillace RM, Miller D et al.. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther 2011; 10: 1059-1071.
15. Hartford CM, Desai AA, Janisch L et al.. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 2009; 15: 1428-1434.
16. Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 2006; 5: 1065-1073.
17. Garnock-Jones KP, Keating GM. Everolimus: in advanced renal cell carcinoma. Drugs 2009; 69: 2115-2124.
18. Sankhala K, Mita A, Kelly K et al.. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 2009; 4: 135-142.
19. Simpson D, Curran MP. Temsirolimus: in advanced renal cell carcinoma. Drugs 2008; 68: 631-638.
20. Berk L, Mita MM, Kreisberg J et al.. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. Cancer Chemother Pharmacol 2012; 69(4): 1369-1377.
21. van Glabbeke M, Verweij J, Judson I et al.. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-549.
22. Schwartz GK. Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. J Clin Oncol 2011; 29(suppl; abstr 10000).
23. Van Der Graaf WT. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 2011; 26(suppl; abstr LBA10002).
24. Mita A, Britten CD, Poplin E et al.. Deforolimus trial 106-a phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669). J Clin Oncol 2008; 26(suppl; abstr 3509).